Build your first embedded data product now. Talk to our product experts for a guided demo or get your hands dirty with a free 10-day trial.
May 19, 2025
📅 Originally aired: June 3, 2025
Watch the replay and catch up at your own convenience!
Dashboards are everywhere—but are they actually helping users make better decisions? In this interactive panel discussion, four industry experts unpack the key insights from our 2025 State of Dashboards research report.
We discussed:
Whether you're a product builder, data leader or founder, this is the conversation you don’t want to miss.
Sara Archer
Chief Revenue Officer at ChartMogul
Analytics advocate, churn fighter, and believer in “opinionated” insights.
Krzysztof (Kris) Szyszkiewicz
Co-founder at Value Ships
Pricing guru, soy sauce philosopher, and Excel export skeptic.
Thomas De Clerck
Co-founder at Luzmo
SaaS analytics veteran, customer-first thinker, and personalization champion.
Moderated by Jonathan Wuurman
VP Marketing at Luzmo
Cap-wearing host and dashboard myth-buster.
💡 “Data is not insight.” — Sara
💬 “Opinionated analytics means offering strong defaults, not limitless options. Trust us to define churn—then explore further if you want.”
💡 “If users export your data, you're just a broker. Not an insight provider.” — Kris
💬 “You want to charge more for analytics? Make dashboards worth staying in.”
💡 “Certified scuba divers welcome. But let surface users breathe too.” — Thomas
💬 “Not everyone needs deep analytics. Some just need a quick, satisfying answer.”
💡 “AI helps ask the right questions, but humans still need to know what to ask.” — Kris
💬 “It’s not about replacing analysts. It’s about making everyone a little more data fluent.”
All stats mentioned in this webinar come from our 2025 survey of +200 SaaS leaders. Dive into the interactive report to explore pain points, trends, and solutions for in-app analytics, built using Luzmo’s own SDK.
Build your first embedded data product now. Talk to our product experts for a guided demo or get your hands dirty with a free 10-day trial.